A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation

Figure 7

The Kaplan-Meier estimates of patient survival in (a) all subjects converted to sirolimus (𝑛=484), (b) subjects converted during the first posttransplant year (𝑛=187), and (c) subjects converted later after transplant (𝑛=297). Lines indicate principal treatment regimen: SRL ± MMF (solid line); SRL + CsA (dotted line); SRL + TAC (dashed line). There were no significant differences between treatment combinations.

(a)

(b)

(c)